Literature DB >> 16041051

Infectivity of Cryptosporidium hominis and Cryptosporidium parvum genotype 2 isolates in immunosuppressed Mongolian gerbils.

Asiya Baishanbo1, Gilles Gargala, Agnès Delaunay, Arnaud François, Jean-Jacques Ballet, Loïc Favennec.   

Abstract

One-month-old dexamethasone-immunosuppressed Mongolian gerbils were challenged with 1 oocyst to 2 x 10(5) oocysts from two isolates genotyped as Cryptosporidium hominis and C. parvum (genotype 2), respectively. A similar dose-dependent gut infection was obtained, and the initial genotype maintained for 21 to 22 days. The data suggest that immunosuppressed gerbils provide a reliable rodent model of persistent C. hominis infection.

Entities:  

Mesh：

Year:  2005        PMID： 16041051      PMCID： PMC1201256          DOI： 10.1128/IAI.73.8.5252-5255.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  39 in total

1.  Animal propagation and genomic survey of a genotype 1 isolate of Cryptosporidium parvum.

Authors:  G Widmer; D Akiyoshi; M A Buckholt; X Feng; S M Rich; K M Deary; C A Bowman; P Xu; Y Wang; X Wang; G A Buck; S Tzipori
Journal:  Mol Biochem Parasitol       Date:  2000-05       Impact factor: 1.759

2.  Oral dosing of neonatal mice with sucrose reduces infection with Cryptosporidium parvum.

Authors:  J A Harp
Journal:  J Parasitol       Date:  1999-10       Impact factor: 1.276

3.  Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice.

Authors:  Pablo C Okhuysen; Stephen M Rich; Cynthia L Chappell; Kevin A Grimes; Giovanni Widmer; Xiaochuan Feng; Saul Tzipori
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

4.  Inter-laboratory comparison of the CD-1 neonatal mouse logistic dose-response model for Cryptosporidium parvum oocysts.

Authors:  D G Korich; M M Marshall; H V Smith; J O'Grady; Z Bukhari; C R Fricker; J P Rosen; J L Clancy
Journal:  J Eukaryot Microbiol       Date:  2000 May-Jun       Impact factor: 3.346

5.  Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.

Authors:  Xunde Li; Philippe Brasseur; Patrice Agnamey; Denis Leméteil; Loïc Favennec; Jean-Jacques Ballet; Jean-François Rossignol
Journal:  Folia Parasitol (Praha)       Date:  2003-03       Impact factor: 2.122

6.  Comparative efficacy evaluation of dicationic carbazole compounds, nitazoxanide, and paromomycin against Cryptosporidium parvum infections in a neonatal mouse model.

Authors:  B L Blagburn; K L Drain; T M Land; R G Kinard; P H Moore; D S Lindsay; D A Patrick; D W Boykin; R R Tidwell
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Genetic analysis of a Cryptosporidium parvum human genotype 1 isolate passaged through different host species.

Authors:  D E Akiyoshi; X Feng; M A Buckholt; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Cryptosporidium hominis n. sp. (Apicomplexa: Cryptosporidiidae) from Homo sapiens.

Authors:  Una M Morgan-Ryan; Abbie Fall; Lucy A Ward; Nawal Hijjawi; Irshad Sulaiman; Ronald Fayer; R C Andrew Thompson; M Olson; Altaf Lal; Lihua Xiao
Journal:  J Eukaryot Microbiol       Date:  2002 Nov-Dec       Impact factor: 3.346

Review 9.  Genomics and genetics of Cryptosporidium parvum: the key to understanding cryptosporidiosis.

Authors:  Giovanni Widmer; Lunhui Lin; Vivek Kapur; Xiaochuan Feng; Mitchell S Abrahamsen
Journal:  Microbes Infect       Date:  2002-08       Impact factor: 2.700

10.  Pathogenesis of human and bovine Cryptosporidium parvum in gnotobiotic pigs.

Authors:  Sonia J Pereira; Norma E Ramirez; Lihua Xiao; Lucy A Ward
Journal:  J Infect Dis       Date:  2002-08-05       Impact factor: 5.226
View more
  8 in total

Review 1.  Cryptosporidiosis: environmental, therapeutic, and preventive challenges.

Authors:  S Collinet-Adler; H D Ward
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-06-04       Impact factor: 3.267

Review 2.  A hundred-year retrospective on cryptosporidiosis.

Authors:  Saul Tzipori; Giovanni Widmer
Journal:  Trends Parasitol       Date:  2008-03-07

3.  Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.

Authors:  G Gargala; A Baishanbo; L Favennec; A François; J J Ballet; J-F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Efficacy of clofazimine and nitazoxanide combination in treating intestinal cryptosporidiosis and enhancing intestinal cellular regeneration in immunocompromised mice.

Authors:  Marwa Esmat; Amany A Abdel-Aal; Maisa A Shalaby; Manal Badawi; Hala Elaskary; Ahmed Badawi Yousif; Mennat-Elrahman A Fahmy
Journal:  Food Waterborne Parasitol       Date:  2022-05-04

5.  Generation of whole genome sequences of new Cryptosporidium hominis and Cryptosporidium parvum isolates directly from stool samples.

Authors:  Stephen J Hadfield; Justin A Pachebat; Martin T Swain; Guy Robinson; Simon Js Cameron; Jenna Alexander; Matthew J Hegarty; Kristin Elwin; Rachel M Chalmers
Journal:  BMC Genomics       Date:  2015-08-29       Impact factor: 3.969

6.  Individual subject meta-analysis of parameters for Cryptosporidium parvum shedding and diarrhoea in animal experimental models.

Authors:  A D Adell; W A Miller; D J Harvey; E Vanwormer; S Wuertz; P A Conrad
Journal:  Epidemiol Infect       Date:  2012-10-16       Impact factor: 4.434

Review 7.  Assessing viability and infectivity of foodborne and waterborne stages (cysts/oocysts) of Giardia duodenalis, Cryptosporidium spp., and Toxoplasma gondii: a review of methods.

Authors:  Angélique Rousseau; Stéphanie La Carbona; Aurélien Dumètre; Lucy J Robertson; Gilles Gargala; Sandie Escotte-Binet; Loïc Favennec; Isabelle Villena; Cédric Gérard; Dominique Aubert
Journal:  Parasite       Date:  2018-03-19       Impact factor: 3.000

8.  Cryptosporidium parvum: determination of ID₅₀ and the dose-response relationship in experimentally challenged dairy calves.

Authors:  J A Zambriski; D V Nydam; Z J Wilcox; D D Bowman; H O Mohammed; J L Liotta
Journal:  Vet Parasitol       Date:  2013-04-20       Impact factor: 2.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.